PMID- 6465859
OWN - NLM
STAT- MEDLINE
DCOM- 19840824
LR  - 20131121
IS  - 0250-7005 (Print)
IS  - 0250-7005 (Linking)
VI  - 4
IP  - 3
DP  - 1984 May-Jun
TI  - Adjuvant immunotherapy of N-[4(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced 
      bladder tumors.
PG  - 209-13
AB  - The prophylactic effect of maltose tetrapalmitate (MTP), a newly developed non 
      specific immunoadjuvant in preventing or delaying bladder cancer induction by 
      N-[4(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT) or in reducing the growth 
      rate of the induced tumor was compared to other well-known immunoadjuvants (BCG, 
      C. parvum, levamisole and pyran copolymer). The evaluation of the prophylactic 
      role of immunoadjuvants demonstrated that MTP, levamisole and C. parvum were the 
      most effective in prolonging animal survival. MTP was found superior to either of 
      them in reducing the tumor size. The development of lung metastasis was lower in 
      the group receiving MTP or C. parvum. Next, MTP was studied for its therapeutic 
      effect against primary FANFT induced tumor. The subcutaneous (s.c.) and oral 
      routes of MTP administration and their combination with intravesical route were 
      tried. Combinations of intravesical with s.c. or oral MTP were most effective in 
      reducing tumor size, obtaining lower metastases along with greater mononuclear 
      lymphocyte infiltration in the primary tumor.
FAU - Ibraheim, E H
AU  - Ibraheim EH
FAU - El Kappany, H
AU  - El Kappany H
FAU - Nigam, V N
AU  - Nigam VN
FAU - Brailovsky, C A
AU  - Brailovsky CA
FAU - Madarnas, P
AU  - Madarnas P
FAU - Elhilali, M M
AU  - Elhilali MM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (BCG Vaccine)
RN  - 0 (Bacterial Vaccines)
RN  - 0 (Glycolipids)
RN  - 27100-68-1 (Pyran Copolymer)
RN  - 2880D3468G (Levamisole)
RN  - 74764-16-2 (maltose tetrapalmitate)
RN  - 7N99PZG62O (FANFT)
SB  - IM
MH  - Adjuvants, Immunologic/*therapeutic use
MH  - Animals
MH  - BCG Vaccine/therapeutic use
MH  - Bacterial Vaccines/therapeutic use
MH  - FANFT
MH  - Female
MH  - Glycolipids/*therapeutic use
MH  - Immunotherapy
MH  - Levamisole/therapeutic use
MH  - Propionibacterium acnes/immunology
MH  - Pyran Copolymer/therapeutic use
MH  - Rats
MH  - Rats, Inbred F344
MH  - Urinary Bladder Neoplasms/chemically induced/pathology/*therapy
EDAT- 1984/05/01 00:00
MHDA- 1984/05/01 00:01
CRDT- 1984/05/01 00:00
PHST- 1984/05/01 00:00 [pubmed]
PHST- 1984/05/01 00:01 [medline]
PHST- 1984/05/01 00:00 [entrez]
PST - ppublish
SO  - Anticancer Res. 1984 May-Jun;4(3):209-13.